Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NBIX – Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.
NBIX
$125.42
Name : Neurocrine Biosciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $12,412,290,048.00
EPSttm : 2.95
finviz dynamic chart for NBIX
Neurocrine Biosciences, Inc.
$125.42
1.02%
$1.29

Float Short %

3.66

Margin Of Safety %

-7

Put/Call OI Ratio

0.6

EPS Next Q Diff

1.85

EPS Last/This Y

2.7

EPS This/Next Y

2.22

Price

125.46

Target Price

160

Analyst Recom

1.37

Performance Q

10.02

Relative Volume

0.89

Beta

0.25

Ticker: NBIX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02NBIX124.610.830.0310337
2025-06-03NBIX125.060.820.0710439
2025-06-04NBIX124.620.810.0010477
2025-06-05NBIX124.640.810.0010481
2025-06-06NBIX125.50.810.0010505
2025-06-09NBIX125.720.816.2910506
2025-06-10NBIX124.820.800.7310533
2025-06-11NBIX124.190.780.7010669
2025-06-12NBIX125.070.790.0010676
2025-06-13NBIX124.40.781.0010716
2025-06-16NBIX1250.780.1010715
2025-06-17NBIX124.90.780.0310722
2025-06-18NBIX127.350.780.0410751
2025-06-20NBIX126.550.760.0710885
2025-06-23NBIX125.80.620.205945
2025-06-24NBIX128.540.620.015971
2025-06-25NBIX128.050.600.006071
2025-06-26NBIX126.760.600.366083
2025-06-27NBIX125.40.600.366083
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02NBIX124.57-8.3135.66.10
2025-06-03NBIX125.00-8.3129.06.10
2025-06-04NBIX124.54-8.3124.06.10
2025-06-05NBIX124.61-8.3127.16.10
2025-06-06NBIX125.45-8.3131.16.10
2025-06-09NBIX125.73-8.3128.46.10
2025-06-10NBIX124.78-8.3121.46.10
2025-06-11NBIX124.15-8.3123.26.10
2025-06-12NBIX125.01-8.3131.26.10
2025-06-13NBIX124.48-8.3123.76.10
2025-06-16NBIX124.99-8.3129.96.10
2025-06-17NBIX124.89-8.3126.06.10
2025-06-18NBIX127.31-8.3139.96.10
2025-06-20NBIX126.55-8.3122.56.10
2025-06-23NBIX125.83-8.3122.76.10
2025-06-24NBIX128.16-8.3139.46.10
2025-06-25NBIX127.81-8.3124.66.10
2025-06-26NBIX126.79-8.3121.16.10
2025-06-27NBIX125.46-8.3119.86.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02NBIX-8.260.094.22
2025-06-03NBIX-8.260.094.22
2025-06-04NBIX-8.220.094.22
2025-06-05NBIX-8.220.094.22
2025-06-06NBIX-8.220.094.22
2025-06-09NBIX-8.220.174.22
2025-06-10NBIX-8.220.174.22
2025-06-11NBIX-8.220.174.26
2025-06-12NBIX-8.220.174.26
2025-06-13NBIX-8.220.174.26
2025-06-16NBIX-8.220.174.26
2025-06-18NBIX-8.220.174.26
2025-06-20NBIX-8.200.174.26
2025-06-23NBIX-8.200.174.26
2025-06-24NBIX-8.200.174.26
2025-06-25NBIX-8.200.174.26
2025-06-26NBIX-8.200.173.66
2025-06-27NBIX-8.200.173.66
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

0.08

Avg. EPS Est. Current Quarter

1.5

Avg. EPS Est. Next Quarter

1.93

Insider Transactions

-8.2

Institutional Transactions

0.17

Beta

0.25

Average Sales Estimate Current Quarter

653

Average Sales Estimate Next Quarter

719

Fair Value

116.13

Quality Score

75

Growth Score

99

Sentiment Score

47

Actual DrawDown %

20.6

Max Drawdown 5-Year %

-46.4

Target Price

160

P/E

42.53

Forward P/E

21.06

PEG

1.22

P/S

5.14

P/B

4.9

P/Free Cash Flow

25.22

EPS

2.95

Average EPS Est. Cur. Y​

6.1

EPS Next Y. (Est.)

8.32

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.68

Relative Volume

0.89

Return on Equity vs Sector %

-11.8

Return on Equity vs Industry %

4.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

119.8
Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading